The IPO window is barely open, so acquisitions are doing almost all the work, and the acquirer list has some genuinely new names on it.
Exits are the clearest read on what a digital health startup is actually worth once the venture money runs out, and 2026's exit data shows the buyer pool widening in a direction few founders were planning for two years ago.
A buyer list that no longer looks like healthcare
Of 282 recent digital health exits, 268, or 95%, were acquisitions rather than IPOs, according to Galen Growth.
In February 2026, Hims & Hers agreed to acquire Australian telehealth company Eucalyptus for up to $1.15B, including $240M upfront cash, to expand into new international markets. In March, Universal Health Services agreed to acquire Talkspace for around $835M.
OpenAI acqui-hired Torch, a four-person health records startup founded by the team behind the shuttered primary care startup Forward, for roughly $100M in equity, to support its ChatGPT Health product. Roche acquired pathology AI platform PathAI for $1.05B. In Europe, Kaia Health sold for $285M and Gleamer for $266.9M, both on the strength of built-up clinical evidence and regulatory clearance. The quarter's single IPO was Generate Biomedicines, which raised $400M.
These exits sit against a much larger biopharma and medtech M&A backdrop, where deal value overall reached roughly $96B across 80 deals in H1 2026, $55.1B of that in Q2 alone, according to JPMorgan, giving a sense of the scale of capital moving through healthcare dealmaking generally this year.
The strategic buyer list just got longer
Big Tech and consumer telehealth platforms are now active acquirers of healthcare startups, not just health systems and pharma companies. That widens the realistic exit universe for founders building AI-native health tools or international consumer telehealth brands, categories that didn't have an obvious strategic buyer a few years ago.
OpenAI's Torch acqui-hire valued a four-person team at roughly $25M per head, a striking number on what specialised AI talent is worth to a buyer building a health product from scratch.
It also means the "who might acquire us" list every founder should be building now looks meaningfully different than it did in 2023, and probably includes at least one name outside traditional healthcare entirely.
The governance question Roche just created
Watch whether other large technology companies follow OpenAI's acqui-hire playbook for small, specialised health AI teams, since that is a much faster path to market than building in-house.
Also watch how Roche's ten pharma partners on PathAI, including Gilead, MSD, Novo Nordisk and GSK, respond now that a previously neutral platform is an owned Roche asset, since that governance question could reshape how startups pitch "neutral" AI infrastructure to competing partners going forward. A platform that markets itself as neutral infrastructure to multiple competitors is making an implicit promise, and Roche's move just tested what happens when that promise breaks.
